Acumen Pharmaceuticals, Inc. Stock Price, News & Analysis

Acumen Pharmaceuticals (NASDAQ: ABOS) has appointed Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality. Dr. Schacterle brings over 30 years of experience in regulatory affairs and quality assurance, with expertise in central nervous system diseases. She previously served as Senior VP of R&D Strategy at Sage Therapeutics, where she led regulatory efforts for the first postpartum depression treatment approval. She joins as the company advances its Alzheimer's disease therapeutic candidate, sabirnetug, which is currently in Phase 2 clinical trials across five countries. Dr. Schacterle replaces Dr. Janice Hitchcock, who is retiring after successfully leading the regulatory strategy for the Phase 1 INTERCEPT-AD study and Phase 2 ALTITUDE-AD study.

Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing a novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment, has scheduled its third quarter 2024 financial results release for November 12, 2024. The company will host a conference call and audio webcast at 8:00 a.m. ET on the same day to discuss business updates and financial performance. Interested participants must pre-register at least one day in advance to receive dial-in information.

Acumen Pharmaceuticals presented data on using pTau217 assay as an efficient screening tool for their Phase 2 ALTITUDE-AD clinical trial of sabirnetug for early Alzheimer's disease. The assay, with a threshold of ≥0.15 pg/mL, effectively identifies potential participants likely to have amyloid in the brain, reducing unnecessary amyloid PET scans and lumbar procedures. 74% of participants with elevated pTau217 met amyloid burden eligibility requirements, compared to 40% in their Phase 1 trial without this screening approach. The study is enrolling at 75 sites across multiple regions, with completion expected in first half of 2025.

Acumen Pharmaceuticals (NASDAQ: ABOS) announced a late-breaking presentation at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) conference in Madrid. The presentation will focus on their screening approach using a validated plasma pTau217 assay in the ongoing Phase 2 ALTITUDE-AD clinical trial of sabirnetug (ACU193) for early Alzheimer's disease. The pTau217 biomarker indicates Alzheimer's pathology and is used as an initial screening tool to identify candidates for additional amyloid testing. The presentation will be delivered by Dr. Todd Feaster on October 31, 2024, at 9:30 a.m. CET.

Lucy Therapeutics (LucyTx) has appointed Kim Drapkin as Board Chair to guide the company's strategic direction as it enters clinical trial development. Drapkin brings over 25 years of experience in biotech and pharma, most recently serving as President and CEO of Graphite Bio. LucyTx, which develops small molecule therapies for complex neurological diseases, recently secured $12.5 million in additional funding, bringing its total to $37 million.

The company's approach involves analyzing various disease drivers, including mitochondrial, environmental, and genetic factors, to create detailed knowledge maps and identify unique drug targets. LucyTx currently has three drug discovery programs in its pipeline, with Investigational New Drug (IND) studies planned for next year, focusing on treatments for Rett syndrome, Parkinson's, and Alzheimer's disease.

Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company, has announced its participation in the Bank of America CNS Therapeutics Virtual Conference. The company, which is developing a novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment, will engage in a fireside chat on Monday, Oct. 7, 2024, at 8:00 a.m. ET.

Interested parties can access the live webcast of the event through the Investors tab on www.acumenpharm.com. The webcast will remain archived on the site for 90 days following the conference, allowing those unable to attend the live session to review the discussion at their convenience.

Acumen Pharmaceuticals (NASDAQ: ABOS) has extended its collaboration with Lonza to support the potential future commercial launch of sabirnetug (ACU193), a novel therapeutic targeting toxic soluble amyloid beta oligomers for early Alzheimer's disease treatment. The extended agreement builds upon their existing partnership for drug substance manufacturing and now includes drug product manufacturing services at Lonza's Visp, Switzerland site.

Sabirnetug, currently in Phase 2 clinical trials, is the first humanized monoclonal antibody to demonstrate selective target engagement of AβOs in Alzheimer's patients. Acumen is also evaluating a subcutaneous formulation in a Phase 1 study. The collaboration extension comes as Acumen advances its clinical programs with over 50 Phase 2 sites activated across the U.S., Canada, U.K. and EU.

Acumen Pharmaceuticals (NASDAQ: ABOS) has announced a virtual R&D Day scheduled for Oct. 2, 2024, at 10:00 a.m. ET. The event will focus on the company's strategic vision and the development of sabirnetug, their novel treatment for early Alzheimer's disease (AD) that targets toxic soluble amyloid beta oligomers (AβOs).

The webcast will feature Acumen's management and scientific leadership, along with external key opinion leaders including:

• Dr. Stephen Salloway, Director of the Memory and Aging Program at Butler Hospital and Professor at Brown University
• Dr. Paul Solomon, Founder of the Boston Center for Memory and investigator in the ongoing Phase 2 ALTITUDE-AD trial for sabirnetug

Participants can register for the live conference call and access the webcast through links provided. An archived version will be available on Acumen's website for at least one year.

Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investor Conference. The company, which is developing a novel therapeutic targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment, will engage in a fireside chat on Tuesday, Sept. 10, 2024, at 1:30 p.m. ET.

Investors and interested parties can access the live webcast of the fireside chat through the Investors tab on www.acumenpharm.com. The webcast will remain archived on the website for 90 days following the event, providing an opportunity for those unable to attend the live session to catch up on the discussion.